TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent

Executive Summary

• TempraMed Technologies Ltd. received an additional granted patent in South Korea (Korean Patent Application No. 10‑2021‑7011422) covering its VIVI Box™ thermal‑insulation and smart‑monitoring system.
• The patented technology expands the VIVI Box™ platform to protect a broader range of temperature‑sensitive drugs—including insulin, GLP‑1 therapies, biologics, and other specialty medications—within domestic refrigerators for up to 24 hours without external power.
• The new IP strengthens TempraMed’s commercialization strategy, supporting further partnerships with appliance manufacturers in Asia’s premium refrigeration market and enhancing its global positioning as a leader in medication temperature management.

Key Details

• Patent Information: Granted South Korean patent (Application No. 10‑2021‑7011422) covering VIVI Box™ features such as continuous temperature protection, portable travel solution, and cloud‑based smart content tracking.
• Product Capabilities Highlighted:
• Maintains a stable 8 °C environment for up to 24 hours without external power.
• Prevents freezing and mitigates refrigerator temperature fluctuations.
• Enables remote monitoring and adherence support via cloud integration.
• Target Drug Categories: Insulin, GLP‑1 therapies, biologics, peptides, and other high‑value specialty medications.
• Strategic Impact: Broadens TempraMed’s ability to adapt core technology across multiple drug categories and supports entry into Asia’s premium refrigeration market through potential OEM collaborations.
• Recent Distribution Milestones (contextual): Exclusive agreements in Israel, Turkey, and major European regions with partners such as Guri A.A.O., Dolfin Saglik, and Salomo Executive, expanding retail pharmacy, HMO, and healthcare network reach.
• CEO Quote: Ron Nagar emphasized the patent as a “milestone” that advances the company’s mission to redefine temperature stability for medications worldwide and positions TempraMed to lead the next chapter of innovation.

Notable Quotes

“Being granted this additional patent in South Korea marks an important milestone in our mission to redefine temperature stability and management for medications worldwide,” – Ron Nagar, CEO, TempraMed
“We are building a global platform that protects patient health, reduces medication waste, and redefines medications storage standards around the world.” – Ron Nagar, CEO, Tempma​r​ed